Detalhe da pesquisa
1.
Identification of small-molecule protein-protein interaction inhibitors for NKG2D.
Proc Natl Acad Sci U S A
; 120(18): e2216342120, 2023 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37098070
2.
Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor.
Int J Toxicol
; 32(5): 336-50, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24097127
3.
Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
J Med Chem
; 51(5): 1145-9, 2008 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-18260618
4.
Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2.
Bioorg Med Chem Lett
; 18(17): 4770-3, 2008 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18707880
5.
Effects of Self-Complementarity, Codon Optimization, Transgene, and Dose on Liver Transduction with AAV8.
Hum Gene Ther Methods
; 27(6): 228-237, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27903094
6.
Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members.
Diabetes Ther
; 1(2): 57-92, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22127746
7.
Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.
Diabetes
; 57(6): 1723-9, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18356408